Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 7/20 | 0.37 |
| ▸ | DDB1 known ✓ | Q16531 | 1/20 | 0.33 |
| ▸ | PDE7A known ✓ | Q13946 | 1/20 | 0.33 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL573347 | 0.98 | CRBN (0.38) | CRBNDDB1PDE7ATDP1GAA | |
| SCHEMBL8775591 | 0.78 | — | — | |
| SCHEMBL7884532 | 0.78 | PDE7A (0.50) | CRBNPDE7ATDP1 | |
| SCHEMBL14609564 | 0.78 | PDE7A (0.50) | CRBNPDE7ATDP1 | |
| SCHEMBL8256251 | 0.77 | CRBN (0.36) | CRBNDDB1PDE7ATDP1GAA | |
| SCHEMBL14117697 | 0.74 | GAA (0.37) | CRBNDDB1PDE7ATDP1GAA | |
| SCHEMBL542497 | 0.73 | PDE7A (0.47) | CRBNPDE7A | |
| SCHEMBL630549 | 0.73 | CRBN (0.43) | CRBNDDB1PDE7A | |
| SCHEMBL15014726 | 0.73 | PYGM (0.39) | CRBNDDB1TDP1GAAHPGD | |
| SCHEMBL14117702 | 0.73 | ALDH1A1 (0.37) | CRBNPDE7ATDP1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514859-B2 | Pyrazole pyrimidine derivative and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2026-01-06 | — | — | US | disclosed |
| US-20250049793-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-02-13 | — | — | US | disclosed |
| US-11925641-B2 | Pyrazole pyrimidine derivative and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-03-12 | — | — | US | disclosed |
| CN-108137562-B | Pyrazolopyrimidine derivative and use thereof | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3331877-B1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2021-09-22 | — | — | EP | disclosed |
| US-20210251992-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-08-19 | — | — | US | disclosed |
| US-10960003-B2 | Pyrazole pyrimidine derivative and uses thereof | BIOTHERYX, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10376511-B2 | Pyrazole pyrimidine derivative and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-08-13 | — | — | US | disclosed |
| US-20180214447-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. ISRAELI COMPANY, OF (IL) | 2018-08-02 | — | — | US | disclosed |
| EP-3331877-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021969-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11925641-B2 | Pyrazole pyrimidine derivative and uses thereof | IRAK1, IRAK2, IRAK3 | CRBN 777/4885DDB1 1190/4885PDE7A 1254/4885 |
| US-10960003-B2 | Pyrazole pyrimidine derivative and uses thereof | IRAK1, IRAK2, IRAK3 | CRBN 777/4885DDB1 1190/4885PDE7A 1254/4885 |
| US-20210251992-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | IRAK1, IRAK2, IRAK3 | CRBN 777/4885DDB1 1190/4885PDE7A 1254/4885 |
| US-10376511-B2 | Pyrazole pyrimidine derivative and uses thereof | IRAK1, IRAK2, IRAK3 | CRBN 777/4885DDB1 1190/4885PDE7A 1254/4885 |
| US-20250049793-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | IRAK1, IRAK2, IRAK3 | CRBN 683/4885DDB1 932/4885PDE7A 1318/4885 |
| US-20180214447-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | IRAK1, IRAK2, IRAK3 | CRBN 777/4885DDB1 1190/4885PDE7A 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.